Review of epidemic aminoglycoside resistance worldwide

Mayer, Kenneth H.

doi:10.1016/0002-9343(86)90480-8

Cited by 35 publications

(24 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serratia strains are known to commonly produce AAC(6') (12,25). The gene coding for this enzyme has been shown to be carried on transposons which may conjugate with multiple plasmids and thereby be widely disseminated (15,29). Nontransferable (i.e., chromosomally specified) AAC(6') production by Serratia strains resulting in amikacin resistance without concomitant gentamicin resistance has also been reported (10).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased resistance to amikacin in a neonatal unit following intensive amikacin usage

Friedland

Funk

Khoosal

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Gram-negative isolates from blood and cerebrospinal fluid were monitored for 1 year before and for 1 year after the first-line aminoglycoside in a busy pediatric department was changed from gentamicin to amikacin.In the general pediatric wards, the switch to amikacin resulted in no change in resistance of nosocomial gram-negative infections to either amikacin (0%Yo before and after) or gentamicin (23.9% [before] versus 26.5% [after]). In the neonatal unit, the switch to amikacin was followed by an outbreak of Serratia spp. that were commonly resistant to amikacin but susceptible to gentamicin. This outbreak abated spontaneously. In the year after the change in aminoglycoside usage, the resistance to amikacin of nosocomially acquired gram-negative infections increased from 7.6 to 27.7% (P < 0.001), and the resistance to gentamicin decreased from 71.2 to 60.2% (P = 0.07). The increase in amikacin resistance of gram-negative bacilli other than Serratia spp. has persisted for more than a year after the introduction of amikacin as the sole aminoglycoside. The different effects observed in the two sections of the pediatric department may be related to the more intensive usage of aminoglycosides in the neonatal unit.The effect of predominant amikacin usage on susceptibility of gram-negative bacteria (GNB) to aminoglycosides is well documented (1, 5-7, 11, 13, 17, 19, 22-24, 28, 30). Those studies showed that frequent usage of amikacin usually results in no increase or only a slight increase in resistance to amikacin and a decrease in resistance to other aminoglycosides. However, in none of those studies were communityand hospital-acquired infections analyzed separately. Also, GNB isolated from all sites were included, and except in one study (6), invasive disease was not separated from colonization without invasion. Because all infections were combined, increases in amikacin resistance of nosocomial infections may have been "diluted" by the inclusion of large numbers of community-acquired isolates. Similarly, combining isolates from all sections of a hospital may mask significant changes in a specific area.Further motivation for this study was the lack of information on antimicrobial resistance levels in relation to aminoglycoside usage in developing countries, where overcrowded hospitals with very high rates of patient turnover are common.Because of increasing resistance of GNB to gentamicin, both the neonatal and general pediatric wards of our hospital changed to amikacin as the sole aminoglycoside for suspected GNB infections.The purpose of this study was to record prospectively the effect of intensive amikacin usage on the aminoglycoside resistance patterns of invasive hospital-acquired GNB in a busy pediatric department. MATERIALS AND METHODSPatient population. Baragwanath is the major hospital serving Soweto, South Africa (population of 1 to 2 million).

show abstract

Section: Discussionmentioning

confidence: 99%

“…Since outbreaks due to various pathogens have previously occurred in our neonatal unit (unpublished data), the Serratia outbreak described here may be unrelated to the change in aminoglycoside usage. However, it is likely that amikacin-resistant strains were selected through antibiotic pressure (15).…”

Section: Discussionmentioning

confidence: 99%

Increased resistance to amikacin in a neonatal unit following intensive amikacin usage

Friedland

Funk

Khoosal

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Such non-antibiotic factors may explain in part why increases in prevalence of resistant organisms are so strikingly location-specific. 22 The studies listed in the Table attempted to detect differences in prevalence of resistance after changes in antimicrobial usage. Such investigations of temporal association require additional cautions.…”

Section: Table Changes In Prevalence Of Resistance In Gram-negative Amentioning

confidence: 99%

“…As Mayer notes, "since plasmids may contain multiple resistance genes, each coding for an enzyme that inactivates one or more antibiotics, and since multiple drugs are used in the hospital environment, direct correlation of the use of • specific antibiotics and specific resistance patterns may be obscured." 22 …”

Section: Table Changes In Prevalence Of Resistance In Gram-negative Amentioning

confidence: 99%

Minimizing Antimicrobial Resistance in Hospital Bacteria: Can Switching or Cycling Drugs Help?

McGowan

1986

Infect. Control

View full text Add to dashboard Cite

“…Antibiotics were given intramuscularly for 10 days, as follows: amikacin, 7 mg/kg of body weight every 8 (12,13,21,22,29 …”

mentioning

confidence: 99%

Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis

Pefanis

Giamarellou

Karayiannakos

et al. 1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vivo efficacies of ceftazidime, aztreonam, and the combinations of ceftazidime with amikacin and aztreonam with amikacin were studied in the rabbit left-sided endocarditis model by using two strains of Pseudomonas aeruginosa, one multisusceptible and one multiresistant, in a total of 156 animals. Antibiotics were given intramuscularly for 10 days, as follows: amikacin, 7 mg/kg of body weight every 8 (12,13,21,22,29

show abstract

Review of epidemic aminoglycoside resistance worldwide

Cited by 35 publications

References 55 publications

Increased resistance to amikacin in a neonatal unit following intensive amikacin usage

Increased resistance to amikacin in a neonatal unit following intensive amikacin usage

Minimizing Antimicrobial Resistance in Hospital Bacteria: Can Switching or Cycling Drugs Help?

Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis

Contact Info

Product

Resources

About